The Most Effective Ways to Diagnose HIV: What You Need to Know!
Human Immunodeficiency Virus (HIV) is a serious infection that attacks the body's immune system. Early detection and diagnosis are crucial for managing the disease and ... Read More
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of ... Read More
Eli Lilly completes $2.4bn acquisition of DICE Therapeutics
Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of ... Read More
Acelyrin boosts immunology pipeline through acquisition of ValenzaBio
Acelyrin has acquired ValenzaBio, a privately held clinical-stage biopharmaceutical company, in an all-stock deal. With the acquisition of ValenzaBio, the US- based late-stage clinical biopharma ... Read More
Grifols to acquire German healthcare company Biotest for €1.6bn
Spanish pharma company Grifols has agreed to acquire Tiancheng (Germany) Pharmaceutical, which holds nearly 90% stake of German publicly listed healthcare company Biotest. The deal ... Read More
BirchBioMed reports breakthrough phase 2 trial results for FS2 in treating keloid scars
BirchBioMed, a Canadian clinical-stage immunology company, has unveiled promising results from a phase 2 trial of FS2, its pioneering antifibrotic therapy designed to treat keloid ... Read More
Alexion Pharmaceuticals secures FDA priority review for SOLIRIS in neuromyelitis optica spectrum disorder
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor, SOLIRIS (eculizumab), as a treatment for neuromyelitis ... Read More
Merck to invest $70m in expansion of US biopharma facility
German pharmaceutical giant Merck is set to invest $70 million to expand its EMD Serono research and development (R&D) facility in Billerica, Massachusetts. This major ... Read More